Regulation of Cancer Immune Checkpoints
148,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
74 °P sammeln
  • Gebundenes Buch

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy.

To improve the responses to checkpoint blockadetherapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Autorenporträt
Dr. Jie Xu is a Professor at the Institute of Biological Sciences, Fudan University. He is also an associate editor of BMC Cancer, guest associate editor of Frontiers in Pharmacology, and editorial board member of the Journal of Digestive Disease and Gastrointestinal Tumors. Dr. Xu was selected for an Excellent Young Scholar Award by the National Natural Science Foundation of China, Top-Notch Young Talents in China Award by the Chinese Government, and Tang Scholar Award by the Tang International Foundation. Also serving as a review expert for the Changjiang Scholar Program and National Natural Science Foundation of China, his research focuses on mechanisms that control the functions of cytosolic and transmembrane proteins in the contexts of tumor signaling and interactions with immune cells. Dr. Xu has published more than 50 articles in international journals, with relevant patents transferred to major pharmaceutical groups.